A new report in the Lancet suggests in terms of costs of 'quality-adjusted life years', often spending on new drugs is much less cost effective than money spent on maintaining & improving care across the NHS.

Of course, Big Pharma will always mobilise (use?) patient groups to lobby for new treatments/medicines, and we know that QALY is not the whole story for individuals & their families, but it does suggest NICE might need to be even tougher on drug costs!

#health #NHS
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02352-3/fulltext